October 26, 2016 12:21 AM ET

Company Overview of Karolinska Institutet

Company Overview

Karolinska Institutet is a Swedish university, which specializes in medicine. Several companies in the field of medicine and biotechnology have been founded as a result of the university's research programmes. As a result, Karolinska Institutet cooperates closely with the private sector and has created an investment arm (Karolinska Investment Fund) in order to enhance its scientists' innovations. Founded in 1810, the company is headquartered in Stockholm.

Stockholm,  SE-171-77


Founded in 1810


46 8 728 64 00


46 8 31 11 01

Key Executives for Karolinska Institutet

Vice President
Professor of Environmental Toxicology
Professor of Pharmacology
Professor of Neurobiology
Compensation as of Fiscal Year 2016.

Karolinska Institutet Key Developments

Karolinska Institutet Presents at BIO-Europe Spring 2016, Apr-04-2016 through Apr-06-2016

Karolinska Institutet Presents at BIO-Europe Spring 2016, Apr-04-2016 through Apr-06-2016. Venue: Kistamässan Convention Center, Stockholm, Sweden. Presentation Date & Speakers: Apr-04-2016, Per Svenningsson, Professor, Department of Clinical Neuroscience. Apr-05-2016, Alexander von Gabain, Deputy Vice-Chancellor, Innovation and Commercial Outreach.

Scancell Holdings plc Announces Strategic Collaboration with Karolinska Institutet

Scancell Holdings plc announced that it has embarked on a strategic research collaboration with scientists at the Rheumatology Unit at Karolinska Institutet, led by Professors Lars Klareskog and Vivianne Malmström. The collaboration will further explore the scientific and clinical role of citrullinated proteins in the treatment of cancer. Scancell's Moditope® platform technology overcomes the immune suppression induced by tumours themselves, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. This is achieved by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes, which overcome self-tolerance and destroy tumour cells. The teams of Professors Klareskog and Malmström have uncovered a central role for citrullinated proteins in the pathogenesis of the autoimmune disease rheumatoid arthritis. Conversely, Scancell has discovered that citrullinated proteins are also targets on cancer cells and this underpins the use of citrullinated peptides in the Company's Moditope® cancer immunotherapy platform. The groups of Professors Klareskog and Malmström perform research in the area of rheumatology and their work has been published in a number of leading academic journals, including Nature, Lancet, Arthritis & Rheumatism, Nature Medicine, Nature Genetics and Annual Review of Immunology.

Ferring Pharmaceuticals and Karolinska Institutet Sign Collaboration Agreement for Establishment of a Research Center Exploiting the Human Microbiome

Ferring Pharmaceuticals and Karolinska Institutet announced that a collaboration agreement has been signed for the establishment of a research center exploiting the human microbiome. The programme will be fully funded by Ferring Pharmaceuticals and governed by a joint steering committee. The proposed project focuses on therapeutic areas where Ferring has extensive expertise. Karolinska Institutet has a deep understanding of the human microbiome. Parts of the research will be carried out at the Science for Life Laboratory (SciLifeLab) that provides access to a broad technical platform for studying complex microbiological communities in well-defined human material. The collaboration between the two partners form a solid foundation for the ambition of a better understanding of the contribution of the human microbiome to physiology and pathophysiology and opens opportunities for development of novel therapies. The research will be led by Professor Lars Engstrand, Karolinska Institutet, who will serve as director. The center will further establish an internationally competitive infrastructure with focus on translational research in the microbiome field set up to develop a comprehensive mapping of the human microbiome in health and disease.

Similar Private Companies By Industry

Company Name Region
1,618 Strict AB (publ) Europe
100 % El Sverige Ab Europe
100 % Förnybart AB Europe
100-Wattaren Europe
1001 Köksluckor Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Karolinska Institutet, please visit www.ki.se. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.